Chite Asirwa, MD is the CEO of International Cancer Institute, an organisation whose main purpose is to expand education, clinical care and training opportunities in cancer control and research across sub-Saharan Africa (SSA) through multi-sectoral collaborations and partnerships with relevant organisations, both governmental and NGOs.

He is a medical oncologist and hematologist, PD/PI of several access to personalized cancer care and research initiatives including Blueprint programme, Shining Tower programme, clinical trials programme, all geared towards enhancing early detection, promoting primary HPV screening, providing standard of care diagnostics, therapeutics cancer research. He has developed several training programmes including SSA oncology preceptorship training, oncology training for physician assistants (clinical officers), development of oncology nursing training programme in Kenya, medical oncology fellowship programme and assisted in the development of gynaecologic oncology programme.

From 2011 to 2019, he was Director of Academic Model Providing Access to Health Care (AMPATH oncology and haematology consortium) in Kenya. In this role he developed infrastructure for telemedicine at AMPATH, created a robust haematology and oncology outreach programme in rural Kenya and participated in the development of the Kenya national cancer control policies, strategic plans and guidelines by the national Ministry of Health. As PI of various clinical and research programmes, he established multiple myeloma programme, lymphoma programme, functional tumour registry, breast cancer screening and treatment programme, haemophilia and sickle cell diagnostics, treatment and research, EMR for oncology care and screening, a multinational lung cancer control programme (MLCCP - Kenya, South Africa, Lesotho, Tanzania, and Eswatini). He also teaches oncology & hematology at various universities in Africa.
He has also been an active ASCO member through ASCO’s Multidisciplinary Cancer Management Course (MCMC), International Affairs Committee (IAC), and Education Council and as a peer reviewer in ASCO journals. Dr. Asirwa is a member of ASCO Academic Global Oncology Task Force. He is a member of the Board of Directors of ASCO and a committee member of ESMO/ASCO Global curriculum in Medical Oncology WG.
He has also established ICI as a center of excellence in oncology and hematology clinical trials (Phase I, II, III) 
He did his undergraduate training in Kenya and postgraduate (Internal Medicine residency and Hem/Onc fellowship) in the United States.